INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream

Incyte (INCY) has received FDA approval for the label expansion of its Opzelura (ruxolitinib) cream to treat mild to moderate atopic dermatitis in children aged two and older, making it the first topical JAK inhibitor approved for pediatric AD in the U.S. This third U.S. approval for Opzelura, backed by positive Phase III TRuE-AD3 study data, is anticipated to significantly boost the drug's sales, which already totaled $283.2 million in 1H 2025, up 37% year-over-year, thereby supporting Incyte's strategic efforts to diversify its revenue base beyond its primary drug, Jakafi.

Analysis

Incyte has secured a significant regulatory win with the FDA's approval for the label expansion of its Opzelura cream to treat pediatric atopic dermatitis in children as young as two. This approval is pivotal as it makes Opzelura the first topical JAK inhibitor available for this patient group in the United States, opening a new market segment. The drug is already demonstrating strong commercial momentum, with sales reaching $283.2 million in the first half of 2025, a 37% year-over-year increase, which this expansion is expected to bolster further. This development is crucial for Incyte's strategic imperative to diversify its revenue, which remains heavily dependent on its lead drug, Jakafi. The company's diversification efforts are also supported by the strong uptake of other recently approved drugs and a recent label expansion for its oncology drug, Zynyz. This positive pipeline execution is reflected in the stock's performance, which has gained 24.5% year-to-date, significantly outpacing the broader industry's 6% growth.

Key Decisions for Investors

• The FDA approval for Opzelura's label expansion provides a near-term catalyst for revenue growth, reinforcing the bull case for Incyte as it successfully executes on its product pipeline.
• Investors should monitor the sales trajectory of Opzelura following this expanded launch, as its success is a key indicator of the company's ability to de-risk its top line from its heavy reliance on Jakafi.
• Given the stock's significant year-to-date outperformance of 24.5% against the industry's 6%, investors should evaluate if the positive outlook from recent approvals is adequately reflected in the current valuation.